The MTOR gene (Mechanistic Target of Rapamycin) encodes a serine/threonine protein kinase that functions as a central regulator of cell growth, metabolism, proliferation, and survival. MTOR is a member of the phosphoinositide 3-kinase (PI3K)-related kinase family and exists in two distinct complexes: mTORC1 and mTORC2. This gene is critically important in neurodegeneration, with dysregulated mTOR signaling implicated in Alzheimer's disease, Parkinson's disease, and other neurological disorders.
| Attribute |
Value |
| Gene Symbol |
MTOR |
| Full Name |
Mechanistic Target of Rapamycin |
| Chromosomal Location |
1p36.22 |
| NCBI Gene ID |
2475 |
| Ensembl ID |
ENSG00000198793 |
| UniProt ID |
P42345 |
| Gene Type |
Protein coding |
| OMIM |
601231 |
The mTOR protein is a large serine/threonine kinase of approximately 289 kDa. It contains multiple protein domains including HEAT repeats at the N-terminus, a FAT domain, an FRB domain (FKBP12-rapamycin binding), a kinase domain, and an auto-inhibitory domain at the C-terminus.
- HEAT Repeats: Protein-protein interaction domains
- FRB Domain: Rapamycin binding site
- Kinase Domain: Catalytic serine/threonine kinase domain
- Auto-inhibitory Domain: Regulatory insertion
- FATC Domain: C-terminal domain essential for kinase activity
mTOR coordinates cellular responses to nutrients, growth factors, and energy status:
- Protein Synthesis: Via S6K1 and 4E-BP1 phosphorylation
- Autophagy: Inhibits autophagic process
- Metabolism: Regulates glycolysis and lipogenesis
- Cell Growth: Controls cell size and proliferation
- Neuronal Function: Synaptic plasticity, memory formation
| Complex |
Components |
Key Functions |
| mTORC1 |
mTOR, Raptor, mLST8 |
Growth, autophagy, metabolism |
| mTORC2 |
mTOR, Rictor, mLST8 |
Actin cytoskeleton, cell survival |
mTOR dysregulation is central to AD:
- Hyperactive mTOR in AD brains
- Impaired autophagy leads to Aβ and tau accumulation
- mTOR affects synaptic plasticity and memory
- Rapamycin shows benefits in animal models
mTOR signaling in PD:
- Dysregulated in dopaminergic neurons
- Affects alpha-synuclein clearance
- Autophagy impairment in PD
- mTOR inhibition may be protective
- Tuberous Sclerosis: MTOR mutations cause TSC
- Epilepsy: mTOR hyperactivation causes seizures
- Autism: mTOR-related synaptopathy
- Huntington's Disease: mTOR dysfunction
| Variant |
Type |
Condition |
| E1799K |
Missense |
Tuberous sclerosis |
| R905W |
Missense |
Developmental disorders |
| Various |
Loss-of-function |
Autism spectrum |
- Altered mTOR signaling in disease states
- Genetic variants may modify risk
- Somatic mutations in some conditions
- Rapamycin and Analogs: Allosteric mTORC1 inhibitors
- Rapamycin (Sirolimus): Immunosuppressant
- Everolimus: FDA-approved for TSC
- Temsirolimus: Cancer treatment
- ATP-competitive Inhibitors: Target both complexes
- Torin1: Research compound
- AZD8055: In development
- Tuberous Sclerosis: mTOR inhibitors reduce seizures
- Brain Tumors: For TSC-related tumors
- AD Prevention: Clinical trials ongoing
- Complete mTOR inhibition has side effects
- Brain-penetrant inhibitors needed
- Timing of intervention critical
- Autophagy induction balance
| Partner |
Interaction |
| Rheb |
GTPase activator |
| TSC1/2 |
Negative regulation |
| FKBP12 |
Rapamycin binding |
| Raptor |
mTORC1 component |
| Rictor |
mTORC2 component |
- S6K1: Protein synthesis
- 4E-BP1: Translation initiation
- ULK1: Autophagy initiation
- TFEB: Lysosomal biogenesis
- PI3K/AKT/mTOR axis
- AMPK sensing
- MAPK cross-talk
Current research focuses on:
- Understanding mTOR in specific neuronal types
- Developing brain-penetrant inhibitors
- Timing of intervention strategies
- Biomarkers for treatment response
- Combination therapies